Consensus on Medical Nutrition Therapy for Diabesity (CoMeND) in Adults: A South Asian Perspective

Dipti Shruthi,\(^1\) Nitin Kapoor,\(^1\) Rakesh Sahay,\(^2\) Sanjay Kalra,\(^3\) Sarita Bajaj,\(^3\) Arundhati Dasgupta,\(^4\) Dina Shrestha,\(^5\) Guru Dhakal,\(^6\) Mangesh Tiwaskar,\(^7\) Manisha Sahay,\(^8\) Noel Somasundaram,\(^9\) Ravinder Reddy,\(^10\) Saptarshi Bhattacharya,\(^11\) Vijaya Bhaskar Reddy,\(^12\) Vijiya Viswanathan,\(^13\) Darshini Krishnan,\(^14\) Manash Baruah,\(^15\) A K Das\(^16\)

\(^1\)Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India; \(^2\)Non Communicable Disease Unit, The Nossal Institute for Global Health, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia; \(^3\)Department of Endocrinology, Osmania Medical College and Osmania General Hospital, Hyderabad, Telangana, India; \(^4\)Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India; \(^5\)Department of Medicine, Moolchand, New Delhi, India; \(^6\)Department of Medicine, Manipal Hospital, Jodhpur, Rajasthan, India; \(^7\)Department of Medicine, Christian Medical College, Vellore, Tamil Nadu, India; \(^8\)Department of Medicine, Catholic Medical College, Kolkata, West Bengal, India; \(^9\)Department of Endocrinology, Rajiv Gandhi Institute of Postgraduate Medical Education and Research, Pondicherry, Puducherry, India; \(^10\)Department of Medicine, National Hospital of Tuberculosis and Chest Diseases, Dhaka, Bangladesh; \(^11\)Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India; \(^12\)Department of Endocrinology, Rajiv Gandhi Institute of Postgraduate Medical Education and Research, Pondicherry, Puducherry, India; \(^13\)Department of Endocrinology, Rajiv Gandhi Institute of Postgraduate Medical Education and Research, Pondicherry, Puducherry, India; \(^14\)Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India; \(^15\)Department of Endocrinology, Rajiv Gandhi Institute of Postgraduate Medical Education and Research, Pondicherry, Puducherry, India; \(^16\)Department of Endocrinology, Rajiv Gandhi Institute of Postgraduate Medical Education and Research, Pondicherry, Puducherry, India

Abstract: Diabetes and obesity are both increasing at a fast pace and giving rise to a new epidemic called diabesity. Lifestyle interventions including diet play a major role in the treatment of diabetes, obesity and diabesity. There are many guidelines on dietary management of diabetes or obesity globally and also from South Asia. However, there are no global or South Asian guidelines on the non-pharmacological management of diabesity. South Asia differs from the rest of the world as South Asians have different phenotype, cooking practices, food resources and exposure, medical nutrition therapy (MNT) practices, and availability of trained specialists. Therefore, South Asia needs its own guidelines for non-pharmacological management of diabesity in adults. The aim of the Consensus on Medical Nutrition Therapy for Diabesity (CoMeND) in Adults: A South Asian Perspective is to recommend therapeutic and preventive MNT in the South-Asians with diabesity.

Keywords: diabesity guidelines South Asia, medical nutrition therapy South Asia, nutrition therapy for obesity, nutrition therapy for diabetes, diabetes, obesity and diabesity

Introduction

Diabetes and obesity are showing a rising trend and giving rise to a new epidemic called diabesity.\(^1\) One in every ten individuals in the United States suffers from diabetes, and about 90–95% of them have type 2 diabetes (T2DM).\(^2\) About 79% of individuals with diabetes live in low and middle income countries (LMIC).\(^3\)

Diabetes is reaching epidemic proportions in all South Asian countries, and more so in India, Pakistan and Bangladesh (Table 1).\(^4\) If this trend continues, India is projected to have approximately 101 million and 134 million adults with diabetes by 2030 and 2045, respectively.\(^4,5\)

The rising trend in obesity in LMICs of South Asia (Table 1) is linked to improved socioeconomic status, increase in sedentary lifestyle and adoption of a calorie-rich Westernized diet.\(^4,5\)

Background and Rationale

This guideline is prepared to address many gaps in the current day practice of non-pharmacological management of diabesity. There are many guidelines on dietary management of diabetes or obesity globally and also from South Asia. However, there are no guidelines or recommendations that address both diabetes and obesity and thus diabesity in the South Asian region. Additionally, the existing diabetes and obesity guidelines in South Asia do not cover diabesity.

Correspondence: Sanjay Kalra
Bharti Hospital, Kunipura Road, Model Town, Near State Bank of India, Sector 12, Karnal, Haryana, 132001
Tel: +91 9896048555
Email: brideknl@gmail.com
obesity guidelines have more data from the West and minimal data from South Asia.

The South Asian phenotype is very different from the rest of the world. Normal weight obesity (the lean-obese) is a common phenotype in South Asia. South Asian adults have higher body fat, lower skeletal mass, more visceral obesity, higher abdominal obesity, more ectopic fat deposition (in liver, muscle etc) and less subcutaneous fat space at the same or

Table 1 Diabetes and Obesity Burden in South Asia

| Diabetes Estimates (20–79 Years) | India | Pakistan | Bangladesh | Myanmar | Sri Lanka | Afghanistan | Nepal | Bhutan |
|---------------------------------|-------|----------|------------|---------|----------|-------------|-------|--------|
| People with diabetes, in 1,000s | 77,005.6 | 19,369.8 | 8,372.2 | 1,282.7 | 1,232.8 | 1,090.8 | 696.9 | 46.0 |
| Deaths attributable to diabetes | 1,010,262.1 | 158,973.7 | 109,857.3 | 31,288.3 | 15,459.1 | 18,630.3 | 11,678.9 | 326.7 |
| Total diabetes-related health expenditure, USD million | 7,057.4 | 1,612.8 | 535.0 | 235.2 | 244.4 | 182.7 | 56.0 | 7.6 |

Obesity burden in South Asia

- BMI >30 was seen in 30.5% of population; Obesity in women (56.7%) and obesity in men (43.3%) 
- Prevalence of overweight and obesity in urban women was 34% 
- Overweight: 20.6% males and 29.96% females
- Obesity: 4.77% in males and 10.35% in females
- Global BMI vs Asian cut-offs: underweight (7.7% vs 7.7%), normal weight (39.6% vs 26.8%), overweight (37.0% vs 34.3%) and obesity (15.8% vs 31.2%). The community prevalence for abdominal obesity was 58.1% when using Asian cut-offs.
- 2016: 36.9% of adults: male: 32.7% and female: 41.2%
- 2020: Overweight: 19%, general obesity: 33.7% and abdominal obesity: 57.1%
- Nation-wide 2016 survey (overweight/obesity): women 32.87% and men 28.77%
- WHO 2016 data: Overweight: 24.8%, obese: 5.9%

Notes: Data from International Diabetes Federation.
lower body mass index (BMI) as compared to the Western world. Many of these characteristics are genetically determined and unique to the South Asian phenotype.

Even though the dishes from different countries of South Asia look different, they usually have similar macronutrient content across the region. Though the diet in South Asia is often on the higher calorie side (sometimes >3000 calories/day), it does not meet the protein requirements of adults. The South Asian diet is rich in carbohydrates, refined sugar, and processed food and low in fiber, fruits and vegetables. Deep frying, reusing oil for cooking and higher use of trans-fats is common in South Asia. These dietary practices are very different from Western dietary practices.

South Asia is also witnessing increased exposure to the food industry. This along with an increasingly sedentary lifestyle in this region is complicating the diabesity problem further. There is an urgent need to curb this using technology. One way to utilize technology is to use smartphone applications (apps) that track nutrients, food labels, caloric value of food, footsteps, exercise level, etc and offer custom-made solutions. However, these apps have not been properly integrated in the management of diabesity.

Another unique feature in South Asia is paucity of specialists. The majority of individuals with diabetes, obesity and diabesity are managed by their primary care physicians. With few specialists in South Asia, it is difficult to give person-centric care. Hence, there is an urgent need to formulate practice guidelines for the physicians to follow. Smartphone apps can help patients maintain a healthy diet and lifestyle. They can be useful tools to provide patient-centric care to manage day to day nutrient intake and calorie intake and expenditure.

Medical nutrition therapy (MNT), or dietary advice given by a trained health care professional (HCP), plays a significant role in management of diabesity. However, MNT lacks proper understanding and a structured delivery approach in South Asia. Hence, there is a felt need to train more physicians in diabesity MNT care in South Asia.

Thus, South Asia needs its own guidelines for non-pharmacological management of diabesity in adults due to various reasons discussed in this section. The aim of the Consensus on Medical Nutrition Therapy for Diabesity (CoMeND) in Adults: A South Asian Perspective is to recommend therapeutic and preventive MNT in South Asians suffering from diabesity.

### Methodology

A group of general medicine, endocrine and obesity experts from South Asian countries, that is, Bangladesh, Bhutan, India, Nepal and Sri Lanka, met on January 17, 2020 to frame the Consensus on Medical Nutrition Therapy for Diabesity (CoMeND) in Adults: A South Asian Perspective.

Global and South Asian data on diabetes and obesity was reviewed in detail prior to the meeting. The following guidelines were studied in detail: the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) clinical practice guidelines for obesity, the American Diabetes Association (ADA) Standards of Medical Care in Diabetes for “Obesity Management for the Treatment of Type 2 Diabetes” and “Lifestyle Management”, a position statement from the Academy of Nutrition and Dietetics, the Research Society for the Study of Diabetes in India (RSSDI) clinical practice recommendations for the management of type 2 diabetes mellitus, other food-based dietary guidelines, the European Association for the Study of Obesity (EASO) position paper, and guidelines and recommendations for South Asia and India. Several review articles and landmark trials on non-pharmacological management of obesity/diabetes/diabesity were also reviewed for formulating the Consensus. Patient-centered care and its benefits in diabesity were also explored.

The first draft of the recommendations was prepared and circulated amongst the experts prior to the meeting for their detailed review. At the meeting, the experts provided suggestions, comments and opinions on the draft. The draft was then revised based on the discussions during the meeting and re-circulated among the experts for their final suggestions. Post this, the draft was finalized and approved by the experts and sent for publication.

### Overview of Recommendations

The recommendations on non-pharmacological management of diabesity in adults are considered under the following headings:

(I) Screening and Diagnosis

(II) Staging

(III) Medical Nutrition Therapy

- Definition
- Indications
- Goals
- Types of Diets
Screening and Diagnosis
Recommendation for Screening and Diagnosis
For screening and diagnosis of diabesity, the following should be done:5,29

1. History: Detailed history is taken to find the root cause of weight gain (Figure 1). This helps individualize patient treatment based on the identified causes.30
2. Physical exam: Double chin, dorso-cervical pad of fat, ectopic fat as in sub-scapular, axillary and infra-axillary regions are seen in South Asians. Other things that should be looked for are acanthosis nigricans, xanthelasma, arcus, tendon xanthoma, abdominal striae, gynecomastia, thyroid nodules/swellings.
3. Anthropometry: Height, weight, waist circumference, waist:hip ratio, and body mass index (BMI) should be measured. Other optional investigation: percentage body fat. The South Asian ethnicity specific cut-offs should be used for these obesity indicators as proposed below:31
   • BMI of $\geq 23$ kg/m$^2$ should be considered as overweight and $\geq 25$ kg/m$^2$ as obese (Table 2). This is

Figure 1 Root causes of diabesity.
Notes: Data from Kapoor et al.32
in agreement with ADA, WHO and Indian consensus group recommendations for BMI cut-off in Asians.\(^{21,32-34}\)

- At BMI of \(\geq 23\) kg/m\(^2\) screening for diabetes should be initiated.\(^{21,32}\)
- Waist circumference indicates visceral fat and is a useful predictor of cardiometabolic risk and can be combined with BMI. It can be measured at regular intervals to note decrease in visceral fat.\(^{35}\)
- Other anthropometric measures which can be combined with BMI include: the ratio of waist circumference to hip circumference (waist:hip ratio ([WHR]), and the ratio of waist circumference to height (waist:height ratio).\(^{36}\)
- Body fat percentage and visceral adipose tissue estimation, though currently used only in the research setting, has significant relevance in the South Asian population.\(^{6}\) As per the American Society of Endocrinologists, the cut-off for total body fat percentage is 35% for women and 25% for men; however, for Asians, a cut-off of 20.6% in men and 33.4% in women has been suggested.\(^{7}\)

4. Laboratory tests: Glycated hemoglobin (HbA1c), fasting and postprandial glucose, fasting lipid panel and albumin/creatinine ratio should be done. Based on clinical suspicion, other assessments may include uric acid, hepatic transaminases and serum cortisol.

5. The 4 Ms of assessment: The complete diabesity assessment framework should consider the 4 Ms: Metabolic, Mechanical, Mental and Monetary (Table 3). This helps in holistic management of the patients.\(^{30}\)

### Limitations of Obesity Assessment Measures

Physicians often use only BMI for measuring obesity. Though BMI is a very popular method of assessing (screening and diagnosis) obesity, it has some limitations which the clinicians should be aware of:\(^{6,7}\)

1. Asian-specific BMI and not the WHO Global BMI parameters should be used to assess obesity in South Asians.\(^{32,37,38}\)
2. BMI should not be used as the only method to assess obesity. BMI should be combined with, at minimum, a waist circumference to capture adiposity correctly (Table 4).
- BMI does not distinguish between muscle weight and fat weight. Though it has high specificity for obesity, it has very low sensitivity for adiposity. Therefore, approximately 50% of individuals with excess fat fail to be classified as overweight/obese.\(^{39}\)
- BMI is unable to catch body fat distribution, which is a marker of metabolic disturbance, cardiovascular risk and linked to T2DM.\(^{40-42}\)

### Table 2 Body Mass Index (BMI) Criteria for Obesity in Adults

| Category          | Asian\(^{37,38}\) | WHO\(^{17}\) |
|-------------------|-------------------|-------------|
| Underweight       | <18.5             | <18.5       |
| Normal weight     | 18.5–22.9         | 18.5–24.9   |
| Overweight        | 23–24.9           | 25.0–29.9   |
| Obesity Grade I   | 25–29.9 kg/m\(^2\) | 30.0–34.9   |
| Obesity Grade II  | 30–34.9 kg/m\(^2\) | 35.0–39.9   |
| Obesity Grade III | >35 kg/m\(^2\)    | \(\geq 40\) |

### Table 3 The 4 Ms of Diabesity Assessment

| Metabolic          | Mechanical       | Mental          | Monetary       |
|--------------------|------------------|-----------------|----------------|
| Type 2 diabetes    | Sleep apnea      | Cognition       | Education      |
| mellitus           |                  |                 |                |
| Dyslipidemia       | Osteoarthritis   | Depression      | Employment     |
| Hypertension       | Chronic pain     | Attention deficit | Income        |
| Gout               | Reflux disease   | Addiction       | Disability     |
| Fatty liver        | Incontinence     | Psychosis       | Insurance      |
| Gall stones        | Thrombosis       | Eating disorder | Benefits       |
| Polycystic         | Interverigo      | Trauma          | Bariatric supplies |
| ovarian syndrome   |                  |                 |                |
| Malignancy         | Plantar fasciitis| Insomnia        | Weight loss programs |

**Notes:** Data from Kapoor et al.\(^{30}\)

### Table 4 Parameters Used to Define Obesity in South Asians

| Parameter Studied          | Criteria for Overweight/Obesity |
|----------------------------|---------------------------------|
| Body mass index            | >23 kg/m\(^2\)                 |
| Waist circumference        | >90 cm in men and >80 cm in women |
| Waist:hip ratio            | 0.9 in men and 0.8 in women     |
| Body fat percentage*       | >25% in men and >30% in women   |

**Notes:** *As measured by dual energy x-ray absorptiometry (DEXA) scan. Data from Thomas et al.\(^{38}\)
Hence, for anthropometry, as discussed above, BMI should be combined with the waist:height ratio (WHR).

Other investigations which can be combined with BMI, if required, are (not usually done):

1. Dual-energy x-ray absorptiometry (DEXA) or air displacement plethysmography, which accurately assess lean body mass and body fat. DEXA is the gold standard to assess body composition. However, neither of these tests can be used routinely as they are very costly.
2. Measuring body water using bioelectric impedance is a relatively inexpensive method. It compares body fat mass with fat-free mass. However, large inter-individual variations limit its use.

Staging of Obesity
The diabesity therapy is guided by the level of obesity. Hence, physicians should be able to identify the stage of obesity and its biochemical parameters. This can be done using well-designed models. The SECURED (Severity of obesity, Expected prognosis, Comorbid conditions, Urgency of control, Risk of complications, Environmental factors, Dysfunction and disability) model (Table 5) lists the parameters that should be considered while developing patient/person-centered care. The Edmonton Obesity Staging System (EOSS) (Table 6) or the Cardiometabolic Disease Staging (CMDS) system (Table 7) can help identify the stage of obesity and plan the intervention accordingly.

Recommendations
Physicians can use any of the models in Tables 5, 6 and 7 to assess the stage of obesity and plan the diabesity intervention accordingly.

Overview of Management of Diabesity
Diabesity can be managed by non-pharmacological, pharmacological and surgical interventions. Treating obesity is the primary focus. T2DM remission should aim to be a natural progression of weight control. Pharmacotherapy with anti-obesity medications and glucose-lowering agents should be started where required. Surgical interventions should be considered in patients who cannot be managed through anti-obesity medications and glucose-lowering agents. However, irrespective of pharmacological and surgical approach used, the focus should be on lifestyle management which primarily includes focus on diet and physical exercise. BMI may be used to guide the type of intervention in diabesity (Table 8). However, all treatment decisions should be made based on the patient’s general condition, contraindications for pharmacotherapy/surgery and severity of comorbid conditions.

Dietary Concerns in Diabesity
Lifestyle habits need to be changed to prevent and therapeutically cure diabesity, which includes reduced daily calorie intake along with aerobic and strength-building exercises. Many food habits cause obesity/abdominal obesity in South Asians such as (but not limited to):5,11

1. Excess consumption of refined carbohydrates, sweets and sweetened beverages
2. Using saturated fats for cooking
3. Frequent consumption of fried snacks or snacks made with highly saturated fat
4. Low fruit and vegetable intake resulting in low fiber intake
5. Increased intake of calorie-dense food

People with obesity often fail to comply with a diet because they prefer highly processed simple sugar

Table 5 SECURED Model

| S | Severity of obesity | Body mass index, waist circumference |
|---|---------------------|-------------------------------------|
| E | Expected prognosis  | Expected life span                   |
| C | Comorbid conditions | Metabolic, mechanical and mood disturbances |
| U | Urgency of control  | Biomedical or psychosocial issues that require early weight control |
| R | Risk of complications | Risk of malnutrition, gall stones, other complications due to rapid weight loss |
| E | Environmental factors | Socioeconomic factors influencing life with obesity |
| D | Dysfunction and disability | Biopsychosocial dysfunction and disability due to obesity |

Notes: Data from Kalra et al.44
Table 6  Edmonton Obesity Staging System (EOSS)

| EOSS Stage | Level of Obesity and Complications | Biochemical Parameters | Level of Prevention | Intervention |
|------------|------------------------------------|------------------------|---------------------|--------------|
| 0          | No apparent obesity-related risk factors, symptoms, psychopathology, limitations, and/or well-being impairments | No EOSS factors reported | Primordial/ No intervention | Healthy lifestyle to be encouraged |
| 1          | Subclinical obesity risk factors, physical symptoms, psychopathology, functional limitations, and/or well-being impairment is mild | Any of the following: (i) Fasting glucose ≥ 100 mg/dL (ii) Cholesterol ≥ 200 mg/dL (iii) Triglycerides ≥ 150 mg/dL (iv) HDL ≤ 60 mg/dL (v) LDL ≥ 100 mg/dL (vi) SBP ≥ 130 mmHg (vii) DBP ≥ 85 mmHg | Primordial | Lifestyle modification |
| 2          | Established obesity, moderate limitations in activities of daily living, and/or well-being impairment | Any of the following: (i) Fasting glucose ≥ 124 mg/dL (ii) Diagnosed with T2DM or on T2DM medication (iii) Total cholesterol ≥ 240 mg/dL (iv) Triglycerides ≥ 195 mg/dL (v) HDL < 40 mg/dL (men) and < 50 mg/dL in women (vi) LDL ≥ 160 mg/dL (vii) Diagnosed hypercholesterolemia or hyperlipidaemia or hyperlipidaemia or on medication for it (viii) SBP ≥ 140 mmHg (ix) DBP ≥ 90 mmHg (x) Diagnosed hypertension or hypertension medication (xi) Any of the following comorbidities: Sleep apnea, gout, arthritis, anxiety, atherosclerosis, fatty liver, congestive heart failure medication, depression, on blood thinners | Primary | Behavioral therapy with supportive medication therapy for biochemical abnormalities and comorbidities |
| 3          | Established end-organ damage, significant psychopathology, significant functional limitations, and/or well-being impairment | Any of the following: (i) Angina (ii) Heart attack (iii) Heart failure (iv) Thrombosis (v) Coronary artery disease (vi) Coronary obstructive pulmonary disease (vii) Dyspnea (viii) Exercise dyspnea (ix) Coronary artery bypass surgery (x) Stroke | Secondary | Medical therapy/Surgery |
| 4          | Severe (potentially end-stage) disabilities from obesity-related chronic diseases, disabling psychopathology, functional limitations, and/or well-being impairment | No data available to evaluate this stage | Tertiary | Bariatric surgery |

Notes: Data from these studies.44,95,96

Abbreviations: DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.
| Stage | Descriptor | Criteria | Level of Prevention | Intervention |
|-------|------------|----------|---------------------|--------------|
| 0     | Metabolically healthy | No risk factors | Primordial/ No intervention | Healthy lifestyle to be encouraged |
| 1     | One or two risk factors | Have one or two of the following risk factors:  
- High waist circumference (≥80 cm in South Asian women and ≥90 cm in South Asian men)  
- Elevated blood pressure (systolic ≥130 mmHg and/or diastolic ≥85 mmHg) or on antihypertensive medication  
- Reduced serum HDL cholesterol (< 40 mg/dL in men; <50 mg/dL in women)  
- Elevated fasting serum triglycerides (≥150 mg/dL) | Primordial | Lifestyle modification |
| 2     | Metabolic syndrome or prediabetes | Have only one of the following three conditions in isolation:  
- Metabolic syndrome based on three or more of four risk factors: high waist circumference, elevated blood pressure, reduced HDL-C, and elevated triglycerides  
- Impaired fasting glucose (fasting glucose ≥100 mg/dL)  
- Impaired glucose tolerance (2-h glucose ≥140 mg/dL) | Primary | Behavioral therapy with supportive medication therapy for biochemical abnormalities and comorbidities |
| 3     | Metabolic syndrome and prediabetes | Have any two of the following three conditions:  
- Metabolic syndrome  
- IFG  
- IGT | Secondary | Medical therapy/Surgery |
| 4     | T2DM and/or CVD | Have T2DM and/or CVD:  
- T2DM (fasting glucose ≥126 mg/dL or 2-h glucose ≥200 mg/dL or on antidiabetic therapy)  
- Active CVD (angina pectoris, or status after a CVD event such as acute coronary artery syndrome, stent placement, coronary artery bypass, thrombotic stroke, nontraumatic amputation due to peripheral vascular disease) | Tertiary | Bariatric surgery if medically fit |

**Notes:** Data from these studies.

**Abbreviations:** CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus.

---

**Table 8 BMI Cut-Offs for Management of Obesity in South Asians**

| BMI Asian in kg/m² | 23–24.9 Overweight | 25–26.9 Grade I | 27–29.9 Grade I | 30–34.9 Grade II | ≥37.5 Grade III |
|-------------------|------------------|----------------|----------------|-----------------|----------------|
| Therapy           |                  |                |                |                 |                |
| Diet, exercise, behavioral therapy | □              | □              | □              | □               | □              |
| Pharmacotherapy   | □ if comorbidities | □              | □              | □               | □              |
| Bariatric surgery | □ if comorbidities | □              | □              | □               | □              |

**Notes:** Data from these studies.
containing foods instead of complex/raw carbohydrates. High glycemic index food stimulates serotonin secretion, which, apart from providing a feeling of well being, also increases a craving for carbohydrates.\textsuperscript{45}

**Medical Nutrition Therapy**

**Definition**

MNT is the provision of nutritional assessment, advice and follow-up, for prevention and/or management of disease, by a qualified or trained health care provider (HCP). MNT includes dietary, nutritional and culinary advice. It includes both home-made food and medical-grade formulations. As well as diet-related content, MNT also encompasses style of communication and counselling. In the context of diabesity, MNT aims to manage both dysglycemia and adiposity through nutritional intervention.

**Indications of Medical Nutrition Therapy**

MNT should be integrated into care of all individuals who require glucose control and weight management: either to decrease or increase weight or maintain weight.

MNT is ideal for patients who have:\textsuperscript{46}

- Cardio-metabolic comorbidities
- Dietary restrictions due to disease (such as kidney disease)
- A busy lifestyle and lack of resources for healthy cooking
- Chewing, swallowing or dextromotor limitations
- An unwillingness to adhere to a strict diet regime

\textbf{Figure 2} Classification of MNT: therapeutic/preventive.

\textbf{Notes:} Data from these studies.\textsuperscript{46–48}

\textbf{Figure 3} Classification of MNT: home-made/commercial.

\textbf{Notes:} Data from these studies.\textsuperscript{46–48}
Classification of Medical Nutrition Therapy

MNT can be classified based on whether it is being given in a therapeutic or preventive setting (Figure 2), whether it is home-made or a commercial preparation (Figure 3) or depending on method of use (Figure 4).

Goals of Medical Nutrition Therapy

1. Attain and maintain individualized glycemic, blood pressure, lipid and weight goals.
2. Delay or prevent complications.

Goals for Diabetes

The ADA recommends the following goals for diabetes:

- A1C: 7%
- Blood pressure: 120/80 to 140/80 mmHg
- LDL cholesterol: 100 mg/dL
- HDL cholesterol: 40 mg/dL for men; HDL cholesterol 0.50 mg/dL for women
- Triglycerides: 150 mg/dL

Goals for Obesity

According to the Position Statement of the Academy of Nutrition and Dietetics (2016), the weight management should be aimed at:

- Preventing further weight gain
- Reducing body weight

Notes: Data from these studies.
Weight management in certain populations (such as eating disorders, pregnancy, receiving chemotherapy) will need to be individualized to their specific needs. For example, the goals of MNT in gestational diabetes are to support maternal, placental and fetal metabolic requirements. It is the first step to introduction of a healthy eating pattern in mothers and therefore their children for the rest of their lives.

**Challenges of Providing Medical Nutrition Therapy in South Asia**

In the advanced countries, MNT forms an integral part of diabetes and obesity care, is person-centric, and necessary for proper management of the disease as the ‘only therapy’, or as a therapy in addition to pharmacotherapy/surgery. However, in South Asian countries like India, MNT is not covered by insurance. Physicians are not sensitized enough to place as much emphasis on MNT as on pharmacotherapy/surgery. Hence, mainstreaming MNT is a challenge in these regions.

Additionally, most hospital and clinical settings in this region provide pre-printed standardized MNT charts/dietary options/dos and don’ts/list of healthy snacks/macronutrient alternatives etc. There is very little scope for a registered dietician (RD) to make individual specific changes based on medical requirement, psychosocial preference, culinary practices and taste.

It is therefore important to integrate MNT given by an RD into the primary care of a patient with diabesity with an aim to restrict calories, improve metabolic parameters and achieve weight loss.

**Different Types of Diets**

Evidence shows that MNT is effective in reducing weight and resolving T2DM. However, responses to a different diet varied in participants. Each diet type had its own benefits. In the Look AHEAD trial, the arm with intensive lifestyle intervention incorporated partial liquid meal replacement to achieve dietary goals. Participants in the intensive lifestyle intervention group lost significantly more weight than DSE participants at year 1 and year 4 (net difference, −7.9% and −3.9%, respectively).

Depending on the calorie intake, a hypocaloric diet (≤1200 kcal/day) can be a low-calorie diet (LCD; 800 to 1200 kcal/day) and a very-low-calorie diet (VLCD; 200–800 kcal/day). If carbohydrate in VLCD is restricted to about 50 g/day, it is known as a very-low-carbohydrate ketogenic diet (VLCKD). The RSSDI recommends the low-carbohydrate ketogenic diet over the low-calorie diet.

In the DIRECT trial, participants randomized to low fat, Mediterranean and low carbohydrate diets lost approximately 2.9 kg, 4.4 kg and 4.7 kg, respectively. The low carbohydrate arm showed a greater decrease in triglyceride levels than the low fat arm. Only the Mediterranean diet could decrease fasting glucose in patients with diabetes. All groups showed a decrease in insulin levels. Though HDL levels increased in all groups, the low carbohydrate group showed a higher increase in HDL than the low fat group.

In the POUNDS Lost study, weight loss was similar in the low fat/average protein (highest carbohydrate), low fat/high protein, high fat/average protein and high fat/high protein (lowest carbohydrate) arms (2.9 kg vs 3.8 kg, vs 3.9 kg vs 3.5 kg). HDL cholesterol increase was greater with the lowest versus highest carbohydrate diet. All diets except the highest carbohydrate increased fasting insulin.

MNT is also effective as a first-line therapy in gestational diabetes mellitus (GDM). A sub-analysis of the St Carlos GDM Prevention Study showed that Mediterranean diet (MedDiet)-based MNT in GDM resulted in near-normoglycaemia and pregnancy outcomes were similar to women who did not have diabetes during pregnancy.

Diet patterns, composition, quantity, advantages and disadvantages of various types of diets are included in Table 9. This is just for guidance, and many dietary patterns may overlap in a patient.

**Step-Wise Integrated Approach for Medical Nutrition Therapy**

In their white paper on diabetes, Daly et al (2009) note that MNT provides

- more intensive nutrition counselling and a therapy regimen that relies heavily on follow-up and feedback to assist patients with changing their behavior(s)…

MNT cannot be generalized. It has to be individualized to patient need and involve proper diagnosis, nutritional assessment and counselling. MNT needs to be provided
Table 9 Various Types of Diets in Diabesity and Their Advantages and Disadvantages

| Type of Diet                              | Definition                                                                 | Reported Benefits                                                                                                                                       | Reported Limitations                                                                 | Comments                                                                                                                                 |
|-------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Low carbohydrate diet                     | <26% carbohydrates or <130 gm/day<sup>98</sup>                             | Beneficial effect on HbA1c level compared to normal carbohydrate diet; May be beneficial to cardiovascular risk factors, according to summaries of data of triglycerides and HDL-C; Some studies indicated short-term effects on weight loss<sup>99,100</sup> | No evidence to show effect on reducing TC and LDL-C; No significant association with weight loss throughout the duration of intervention.<sup>101</sup> | Water and traditional Indian non-starchy vegetables low in carbohydrate (such as salad greens, cauliflower, cucumber, bottle gourd, cabbage, etc); fat from animal foods, oils, butter, and avocado; and protein in the form of meat, poultry, fish, shellfish, eggs, cheese, nuts, and seeds. Avoids starchy and sugary foods such as rice, potatoes, bread, and sweets.<sup>49</sup> |
| Very-low carbohydrate diet                | <10% carbohydrates or <20–50 gm/day<sup>98</sup>                         | Decreased body weight, triglycerides and DBP and increased HDL-C. Achieved a greater weight loss than those assigned to a low fat diet<sup>102</sup> | Increased LDL.<sup>103</sup> Possible occurrence of diabetic ketoacidosis with SGLT2 inhibitors.<sup>103</sup> | Similar to low-carbohydrate pattern but further limits carbohydrate-containing foods, and meals typically derive more than half of calories from fat. Often has a goal of 20–50 g of non-fiber carbohydrate per day to induce nutritional ketosis.<sup>49</sup> |
| Ketogenic diet                            | No carbohydrates; Avoid excess protein; High fat (>70% of calories)<sup>15,104</sup> | Decreased HbA1c and insulin resistance; Improved lipid profile<sup>105</sup>                                                                                       | Likely reduction in endurance performance; Long-term impact on weight loss and physical activity remains unknown<sup>105</sup> | Lipid profile should be monitored while patient is on this diet and diet adjustments should be made based on the lipid profile.<sup>15</sup> |
| Paleo diet: the 80/20, the autoimmune, the lacto, the autoimmune and the Paleolithic ketogenic<sup>106</sup> | 30% carbohydrate; lean protein of 30–35% daily caloric intake; 40% fat; fiber (up to 45–100 g daily) from non-cereal, plant-based sources<sup>106</sup> | Rapid weight loss; Liver fat reduction; Reduces inflammation; Improves body microbes; Improved lipid profiles and glucose sensitivities; Prevents T2DM and metabolic syndrome; Improves nutrition density, enhances satiety<sup>106,107</sup> | Expensive; Weight loss at 24 months is similar to that achieved by generalized caloric restriction; Side effects; Low calcium intake<sup>106–108</sup> | Diet includes natural environmental foods (lean meat, fish, fruits, vegetables, roots, eggs, and nuts) and eliminates grains, legumes and most processed foods so that it resembles the diet followed by human hunter-gatherer ancestors.<sup>106,108</sup> |
| Intermittent fasting (IF)                 | No food consumed, fasting                                                | Reduction in weight, triglycerides, insulin, adiponectin, SBP, and TC; Lowers risk of CAD; Maintain lean body mass; May be sustainable for long periods of time<sup>107,108</sup> | Weight regain if there is non-adherence/non-compliance; Binge eating on non-fasting days; Weight loss at 24 months is similar to that achieved by generalized caloric restriction<sup>107,108</sup> | Time-restricted IF: Eating only during certain hours of the day, for example 16 hours fasting and eating during remaining 8 hours Complete IF: Not eating at all on fasting days, for example alternate day fasting, twice a week fasting Modified IF: Eating 20–25% of basal calorie needs on fasting days.<sup>108</sup> |

(Continued)
Table 9 (Continued).

| Type of Diet     | Definition                                                                 | Reported Benefits                                                                                                                                                                                                 | Reported Limitations                                                                                                                                                                                                 | Comments                                                                                                                                   |
|------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Atkins diet      | No calorie restriction; Low carbohydrate; Unrestricted protein and fat<sup>108</sup> | Reduction in weight, TG, LDL, TC, TC/LDL ratio, LDL/HDL ratio, leptin, and insulin DBP, SBP, CRP, Improved HDL, insulin sensitivity, and adiponectin<sup>108</sup> | Weight regain; Poor compliance; Fluctuating LDL<sup>108</sup>                                                                                                                                                            | Induction phase (2 weeks)= < 20 g/day carbohydrate  
Weight loss phase: gradually increase carbohydrate by 5 g/day  
Pre-maintenance phase: 40–100 g/day carbohydrates  
Maintenance phase: maintain ideal carbohydrate balance<sup>108</sup> |
| Mediterranean    | 50–55% low glycemic load (GL) carbohydrates; 30% fats; 15–20% protein<sup>108</sup> | Sustained weight loss; Reduction in waist circumference and BMI; HbA1C reduction; Reduced risk of diabetes and insulin resistance; Triglycerides, leptin, CRP lowered; Risk of major cardiovascular events reduced; Increase in HDL and adiponectin; Improves mental health<sup>109–112</sup> | No known limitations                                                                                                                                                                                                  | Include more of: Plant-based food; Fish and other seafood; Olive oil as the main dietary fat source of monounsaturated and polyunsaturated fatty acids (MUFA and PUFA)  
Eat in low to moderation: Dairy products (mainly yogurt and cheese); Wine; <4 eggs/week  
Low frequency and amount: Red meat  
Rare: concentrated sugars or honey<sup>49</sup>|
| DASH diet        | 55% carbohydrates; 27% total fats; 6% saturated fats; 18% protein; fiber: 30 g; cholesterol: 150 mg; potassium: 4,700 mg; calcium: 1,250 mg; magnesium: 500 mg; sodium: ≤1500 mg<sup>113</sup> | Weight loss; Reduction in waist and hip circumference, hip circumference and percent body fat; Improved muscle strength; Reduction in HbA1c and insulin resistance; Improvement in T2DM; Lowered blood pressure; Increased HDL-cholesterol; Lowered triglycerides (Evert et al. 2019; Perry and Guilder 2019<sup>115</sup>) | No known limitations                                                                                                                                                                                                  | More intake of vegetables (five servings per day), fruits (five meals per day), whole intact grains (seven servings per day), low-fat dairy products (two servings per day), lean meat (fish and poultry) (Stwo servings per day), and nuts (2 to 3 times per week)  
Reduced intake: saturated fat, red meat, sweets, sugar-containing beverages, and sodium<sup>49,114,115</sup> |
| Low energy diet  | EASO: 800 kcal/day  
VLEDs, <800 kcal/day; LEDS, 800–1200 kcal/day<sup>49,116,117</sup> | Rapid weight reduction (3–5 months), maintained up to 4 years; 10–15% of body weight can be reduced; T2DM remission possible in overweight and obese<sup>49,116,117</sup> | Not suitable for children, adolescents, pregnant or lactating women, hepatic/renal failure, heart disease, T1DM and elderly  
Possibility of non-adherence, safety issues, risk of eating disorders, high cost, questionable long-term efficacy<sup>49,116,117</sup> | Usually formula LED, VLED and VLCD are used as partial or total meal replacement; Combination of 3–4 products may be used per day<sup>116</sup> |

(Continued)
MNT is recommended by the ADA, RSSD and Indian Council of Medical Research (ICMR) as part of routine care in diabesity.\textsuperscript{15,61} The components of MNT recommended by the ADA, RSSD and ICMR are listed in Table 10.\textsuperscript{15,53,61} Key recommendations for components of MNT were not available from other South Asian regions. Hence, the experts involved in CoMeND studied these recommendations to

Table 9 (Continued).

| Type of Diet                      | Definition                                                                 | Reported Benefits                                                                 | Reported Limitations                                                                 | Comments                                                                                     |
|----------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| Very low calorie ketogenic diet  | Type of VLCD with daily energy intake < 800 kcal but marked daily carbohydrate restriction to \( <30 \) g/day (\( 13\% \) of total energy intake); fat \( \square \) 44% and protein \( \square \) 43%\textsuperscript{118} | Rapid weight loss, positive psychology, increase compliance                         | Not suitable for children, adolescents, pregnant or lactating women, hepatic/renal failure, heart disease, T1DM and elderly | Short-time therapy (maximum 12 weeks)                                                       |
|                                  |                                                                           | Personalized VLCKD: lean mass saved, abdominal fat mass reduced                   |                                                                                       | The ketogenic period (Phases 1–3): \( 600–800 \) kcal/day; Average length is 8–12 weeks but can be prolonged until 80–85\% of the desired weight loss is reached |
|                                  |                                                                           | Preservation of fatty free mass which plays a key role in glucose metabolism      |                                                                                       | Phase 1: Four to six protein preparations of high biological value derived from green peas, eggs, soy and whey are allowed along with low-carbohydrate vegetables. |
|                                  |                                                                           | Personalized VLCKD: Restoration of metabolic flexibility, resting energy expenditure maintained, and diabetes reversal\textsuperscript{17,27,49,118–120} |                                                                                       | Phase 2/3: Lunch or/and dinner are gradually replaced by natural protein meals (meat/fish/eggs/soy). |
|                                  |                                                                           |                                                                                   |                                                                                       | Carbohydrate re-introduction (Phases 4–6): The daily calorie intake ranges between 800 and 1500 kcal/day |
|                                  |                                                                           |                                                                                   |                                                                                       | Phase 4: Foods with the lowest glycemic index like fruit or dairy products                  |
|                                  |                                                                           |                                                                                   |                                                                                       | Phase 5: Foods with moderate glycemic index such as legumes                                  |
|                                  |                                                                           |                                                                                   |                                                                                       | Phase 6: Foods with a high glycemic index (bread, pasta and cereals).\textsuperscript{118}   |
| Vegetarian or vegan              | No or minimal animal-based food                                           | Weight loss; HbA1c reduction; Reduced diabetes risk; Lowering of LDL and non–HDL-cholesterol\textsuperscript{29} | Less acceptability and adherence in non-vegetarians, hence ideal only for vegetarians; Vitamin B12 supplementation may be required; Careful micronutrient planning (zinc, calcium and iron) required, especially in elderly\textsuperscript{121,122} | Vegan diet can be purely vegan (no food from any animal source included), lactovegan (vegan diet that includes dairy products), eggovo (vegan diet that includes eggs and the Jain diet (vegan diet that does not include onions, garlic, roots and tubers).\textsuperscript{121,122} |

Abbreviations: BMI, body mass index; CAD, coronary artery disease; CRP, C-reactive proteins; DASH, Dietary Approaches to Stop Hypertension; DBP, diastolic blood pressure; EASO, The European Association for the Study of Obesity; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SGLT2, sodium-glucose transport protein 2; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TC, total cholesterol.

in a step-wise approach after careful assessment of the patient (Figure 5).\textsuperscript{53,60} MNT advice should be aimed at promoting weight loss without major disruption in a family’s eating practices.\textsuperscript{50} MNT needs careful monitoring and adherence to achieve the desired outcomes. This can only be achieved through a collaborative effort between the patient, family members, RDs, diabetes educators, treating medical team and culinary scientists.\textsuperscript{53,54}
formulate their own recommendations for South Asia. Key features are listed in Table 10.

**Recommendations for Medical Nutrition Therapy**

These recommendations can be divided into three main groups.

**Group A: General Dietary Recommendations**

1. Food portions should be reduced but not cut down drastically. The plate method can be used to control portion size of different major food groups (Figure 6).
2. The diet of a patient with diabesity in South Asia should be planned carefully, keeping in mind the country and region specific influence on culinary diversity, lifestyle and economic condition.\(^{(11,62)}\)
3. Healthy dietary patterns should always be recommended. Diet education should be a part of patient counselling.\(^{(17,63)}\)
4. A hypocaloric diet should be advised and individualized to patient’s need.\(^{(5,29)}\) Appendix I gives the approximate calorific values of commonly cooked food items. This can serve as a guide for calorie planning.
5. Patients should be encouraged to maintain food diaries. These help understand food patterns, emotional eating patterns, and patients’ perceptions of and behaviors towards food.\(^{(17,63)}\)

**Group B: Nutrient and Care**

1. Carbohydrate and saturated fats should be reduced (Table 10).
2. Correct oils (PUFA and MUFA) and cooking methods (steaming, baking, shallow-fat frying, low fat cooking etc) should be advised.\(^{(11)}\)
3. Unless contraindicated (eg as in kidney disease), normal protein diets or supplements should be recommended as most patients in the South Asian region consume much less protein than their RDA.
4. The goals of MNT should be monitored regularly. The frequency of monitoring may need to be
Table 10 Components of MNT: Comparative Analysis of Recommendations by the ADA, RSSDI, ICMR and CoMeND

|                | ADA                                              | RSSDI                                           | ICMR                                           | CoMeND                                          |
|----------------|--------------------------------------------------|-------------------------------------------------|------------------------------------------------|------------------------------------------------|
| **Carbohydrates** |                                                 |                                                 |                                                 |                                                 |
| Recommended intake | ADA does not provide any recommendations due to lack of clinical evidence | 45–65% of total daily calories (minimum intake: 130 g/day) | 55–60% of total daily calories | Try to reduce current carbohydrate intake by 10–15% |
| Fiber/glycemic index | High-fiber diet: increased intake of soluble and insoluble fibers | Intake of fiber-rich foods | Concordant with all current recommendations |                                                 |
| Preferred sources | Fruits, vegetables, whole grains, legumes and dairy products (milk and yoghurt) | Pulses, legumes, coarse grains, sprouted grains, unprocessed vegetables and fruits Substitution of polished white rice with millets and brown rice | Cereals, mixed coarse grains, whole grains (eg, ragi, oats, barley, jowar), whole pulses, whole fruits, salads and soybeans, leafy vegetables, fenugreek seeds Restricted intake of all-purpose flour (maida)-based products | Concordant with all the current recommendations |
| **Proteins** |ihan=|                                               |                                                 |                                                 |
| Recommended intake | Typically 15–20% of total energy in individuals without diabetic kidney disease Recommended daily allowance in individuals with T2DM and compromised renal function: of 0.8 g/kg body weight/day | 10–15% of total daily calories | 10–15% of total daily calories | Try to increase the current protein intake by 10% to a maximum of 1 gram/kg body weight/day |
| Preferred source | Preferred sources: not mentioned | Preferred sources: not mentioned | Vegetable sources, low-fat milk and milk products, fish and lean meat | Concordant with ICMR guidelines |
| **Fats** |                                               |                                                 |                                                 |                                                 |
| Recommended intake | No specified ideal intake | No specified ideal intake | 20–25% total daily calories | Try to minimize visible fat intake |
| Other restrictions | Restricted intake of saturated fats: <10% total daily calories Minimal intake of trans fats Restricted intake of dietary cholesterol: <300 mg/day | Restricted intake of saturated fats: <10% total daily calories Minimal intake of trans fats Restricted intake of dietary cholesterol: <300 mg/day | Restricted intake of saturated fats: <7% total daily calories Minimal intake of trans fats ((hydrogenated vegetable fats) Restricted intake of dietary cholesterol: <300 mg/day | Concordant with all current recommendations |
| Preferred source of MUFA/PUFA | Fatty fish, nuts and seeds | Moderate intake of fish/seafood, chicken without skin and red meat* as a source of PUFA Not recommended: sunflower oil | Groundnut, sesame, cotton seed, rice bran or safflower along with soybean, mustard, canola etc as preferred choices for edible oils containing MUFA and PUFA | Concordant with all current recommendations |

*Continued*
individualized based on patient’s acceptance and adherence to MNT.

5. Any eating disorders identified should be treated as a priority through proper education, counselling and pharmacotherapy.¹⁷,⁶³

**Group C: Medical Nutrition Therapy**

1. MNT should be individualized based on the Degustation Pentad (Figure 7) proposed by Dr. Kalra and colleagues. This pentad is based on a Vietnamese culinary philosophy. It suggests that an individual’s meals should appeal to all five human senses (vision, smell, taste, touch, and hearing).⁵⁴,⁶⁴

2. MNT should be designed such that it incorporates the:
   - Biomedical triplet of diet to provide the right macro-nutrient balance (protein energy) and adequate micronutrients. MNT should be medically/metabolically appropriate and yet low in glycemic index.⁵⁴
   - Comorbidities like dyslipidaemia, renal disease, coeliac disease, hyperuricaemia etc.⁵⁴

3. MNT needs to follow the seven As of dietary choice in order to promote adherence in patients. Thus, it needs to be Appropriate and Accurate for the patient’s needs, easily Absorbed, Affordable, easily Accessible, Acceptable (conform with taste preferences of the individual; have the right aroma) and Attractive (visually appealing) to that individual (Figure 8).⁵³,⁵⁴
   - MNT should be affordable; crafted with locally available food items; conform with local customs, beliefs and taboos; easy to prepare; provide enough alternatives; and consider religious and social practices of the community for which it is being designed.⁵⁴

---

**Table 10 (Continued).**

| Micronutrients and other dietary recommendations | ADA | RSSDI | ICMR | CoMeND |
|-----------------------------------------------|-----|-------|------|--------|
| Sugars and sweeteners                        | Reduced intake of HFCS and sucrose Substitute nutritive sweeteners with non-nutritive sweetener Natural fructose/free fructose from fruits (3–4% of energy intake and not >12) is permissible | Reduced intake of refined sugars Moderate intake of non-nutritive artificial sweeteners Avoid consumption of HFCS | Avoidance of sugar; honey, jaggery Restricted use of artificial sweeteners and avoidance in pregnant/lactating women with diabetes Avoidance of very sweet fruits and fruit juices | Concordant with all current recommendations |

**Notes:**
- particularly in patients with established cardiovascular disease; "insufficient evidence available; "further restriction in patients with diabetes and hypertension. Data from these studies.¹⁵,⁵³,⁶¹

**Abbreviations:** ADA, American Diabetes Association; HFCS, high-fructose corn syrup; ICMR, Indian Council of Medical Research; MUFA, mono-unsaturated fatty acids; PUFA, poly-unsaturated fatty acids; RSSDI, Research Society for the Study of Diabetes in India; T2DM, type 2 diabetes mellitus.
4. Formula MNT can be a:

- Meal replacement plan for patients who have a busy lifestyle or who are not willing to adhere to a strict diet regime.
- Meal replacement for individuals who have limited access to healthy cooking or who have difficulty in calculating calories.

5. MNT should be in concordance with pharmacotherapy, so

- A 3 + 3 meal pattern is recommended with
  - Intensive insulin therapy (basal bolus)
  - Sulfonylureas

- Regular snacks should be suggested for individuals
  - On pre-mixed insulin
  - On human insulin
  - Having a lifestyle involving exertional physical activity.

**Physical Activity and Lifestyle Interventions**

Lifestyle behavior therapies are successful in reducing weight and resolving T2DM. However, the level of benefit seen varies with BMI level. In the Look AHEAD trial, patients in the bottom and top 25% lost
<3% of their body weight and 12 kg at eight years, respectively. Intensive lifestyle intervention produced better results than diabetes support and education. Physical activity can cause modest weight reduction. Its main importance during weight management is that it helps in preserving fat-free mass and maintaining weight. Physical activity promotes cardio-respiratory fitness and reduces cardiovascular risk.17

Recommendations17,63

1. Physical activity counselling should be an integral part of obesity management. This should include advice on building physical activity in everyday life and a supervised structured exercise program under the guidance of an expert.
2. Exercise prescription must be individualized, keeping in mind the patient’s health and fitness status and ability to exercise.
3. Structured exercise levels should be gradually stepped up to levels that are safe for the patient.
4. A higher volume of physical activity is required for weight maintenance than is recommended for the general population for health maintenance.
5. Adequate protein intake should be ensured to build muscle mass during strength training.

Managing Right Food Intake in a Setting of Abundance

Urban areas in South Asia have an abundance of food. The urban population therefore needs to make the right choices in their diet when they are spoilt for choice. Many of the strategies covered in this section, however, pose challenges in lower middle income South Asian countries.

Recommendations

1. Patient education and self-restraint can help people make the right food choices. Health education and moderation in food intake should be started at school level to ensure development of healthy lifestyles and food practices for life.66
2. Restricting access to unhealthy food types may restrict their purchase and consumption and thus may help reduce weight.
3. Healthy food alternatives should be easily available at home and in the workplace.
4. It may be possible to curb obesity by providing more places for exercising and building exercise as a culture.
5. Encouraging use of smartphone apps which provide nutrition and/or exercise and fitness guidance. These apps have comprehensive nutrition databases that tell a user the nutritional content of an item after scanning the barcode, allow them to search for healthy options from restaurant menus and help them recognize food items on a plate. Smartphone sensors use machine learning and symbolic reasoning to recognize and quantify lifestyle activities of patients with diabesity and help them make more informed activity choices if necessary.
6. Proper pricing and promotion strategies need to be implemented to reduce intake of unhealthy food. These strategies include (but are not limited to)11,66–70:
   a. Establishing farmers’ markets in all neighborhoods.
b. Making subsidized fresh fruits and cooked vegetables available in schools.

c. Increasing prices of high-fat and high-sugar foods, especially in school and office cafeterias and neighborhoods (one option is to increase taxes on these). Additionally, low fat/low sugar healthy foods can be made available at affordable prices.

d. Revisiting marketing strategies involving healthy foods.

### Monitoring

Patient adherence to diet and motivation to stay on diet wanes over time if the dietary recommendations are not monitored over time. According to the Academy of Nutrition and Dietetics, the parameters listed in Table 11 should be assessed and monitored for an effective weight management.

### Counselling and Motivation

#### Need for Counselling and Motivation

Stress is associated with overeating, which increases weight. Obesity in turn adds further stress due to development of other comorbidities and because of stigmatization. A study from Southern India on morbidly obese individuals suggested that about 30% of individuals attending an obesity clinic had psychological problems. This leads to a vicious cycle and diabesity management fails. Cognitive behavior therapy (CBT) can help an individual recognize and change behaviors associated with stress and overeating. It can teach an individual to manage stress well.
Recommendations for Counselling

MNT and lifestyle interventions are likely to fail if patients are not kept sufficiently motivated throughout life. Hence, it is very important for physicians to understand their patients well and keep them motivated. The approaches mentioned in Table 12 can be used to guide counselling. However, help from a trained psychologist should be used if the physician feels that the patient needs more rigorous counselling and follow-up to follow recommended diet and lifestyle changes.

1. Diet, exercise and behavioral therapy is recommended with or without drug/surgical therapy (as applicable) and in both preventive and therapeutic settings.

2. HCPs should focus on patient’s QOL and how diabesity is affecting their QOL.

3. Addressing psychological aspects of diabesity care will help in better adherence to therapy.

4. The patient should be given the right to make decisions regarding treatment. The HCP should outline all treatment choices, their benefits and side-effects, to the best of his/her knowledge. However, the physician should guide the treatment decision in the right direction, especially in a low literacy level patient, and where the patient’s decision may cause dire consequences for health.

5. Patient education should be built into diabesity care. This should be reinforced at diagnosis, then annually, at the time of complications/change in treatment and when there is a change in care.

Way Forward in Diabesity
Management in South Asia

Personalized Medicine in Diabesity: Role of Gut Microbes and Genes

Diabesity is a chronic disease influenced by the patient’s nutrient intake, food and beverage consumption, genetic background, microbiome (microbes colonizing in human beings and their genes), and omic profiles including metabolome.

The gut microbiota in a patient with diabesity causes many pathological changes in energy harvest and in the modulation of free fatty acids (mainly butyrate), bile acids, lipopolysaccharides and toll-like receptors. Many other changes have been implicated in diabesity. In a nutshell, these changes result in changes in inflammation, insulin signalling and incretin production and therefore contribute to the development of diabesity.

Figure 9 Diet is the main factor affecting composition of gut microbiota.
Gut microbiota, host (patient with diabesity) and diet form an important trialogue in diabesity. Gut microbiota change with diet, disease, medication and other host factors. Therefore, gut microbiota in patients with diabesity differ from those in healthy individuals. Of these factors, the patient’s diet plays the most important role (Figure 9).

Many genes modify the response to diet and their study can open the path to personalized medicine in diabesity. The POUNDS Lost study was conducted to increase understanding of this area. The study randomized 811 individuals to one of four diets: (20% vs 40% fat and 15% vs 25% protein) to understand the genetic factors that modulate dietary response.

Personalized medicine also combines many environmental factors to predict response to diet. A study showed that an algorithm integrating anthropometrics, blood parameters, dietary habits, gut microbiota and physical activity could accurately predict an individual’s postprandial glycemic response to real-life meals (Figure 10).

Current research in precision and/or personalized nutrition shows the benefits of individually tailoring dietary interventions (including therapeutic intervention to trigger gut microbiota with prebiotics, probiotics and synbiotics). However, this is a new and upcoming field. Further research, especially in the form of large Phase 3 trials, are required to understand the exact benefits of personalized medicine in diabesity.

Patient/Person-Centered Care
Since South Asia is a developing region, it is now time to introduce the Western concept of person-centered or patient-centered care. This means involving patients in their disease care, giving them the right to make treatment decisions, educating them about their disease and taking care of their psychological needs. The Second Diabetes Attitudes, Wishes and Needs (DAWN2) study carried out in seventeen nations, including India, shows that 26.7% of HCPs in India fail to ask their patients how diabetes affects their lives. In contrast, about 55% of patients in India...
reported that their HCPs do not ask them about their QOL with diabetes.\(^4\) Hence, concentrated efforts should be made to integrate person/patient-centered care into the diabesity care algorithm.

**Acknowledgment**

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work, and have given final approval for the version to be published. The authors thank Dr. Chetan Mehndiratta, Mr. Tammay Agrawal of Signutra Inc for execution of the study, and Dr. Kokil Mathur and Dr. Punit Srivastava of Mediception Science Pvt Ltd (www.mediception.com) for providing medical writing support in the preparation of this manuscript, funded by Signutra Inc. India.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Kumar N, Puri N, Marotta F, et al. Diabesity: an epidemic with its causes, prevention and control with special focus on dietary regime. *Func Foods Health Dis*. 2017;7(1):1–16. doi:10.31989/ffhld.v7i1.280

2. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. *Circ Res*. 2016;118(11):1723–1735. doi:10.1161/CIRCRESAHA.115.306825

3. IDF. IDF Diabetes Atlas 9th edition 2019. International Diabetes Federation; 2019. Available from: https://diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf. Accessed December 24, 2019.

4. Hills AP, Misra A, Gill JMR, et al. Public health and health systems: implications for the prevention and management of type 2 diabetes in south Asia. *Lancet Diabetes Endocrinol*. 2018;6(12):992–1002. doi:10.1016/S2213-8587(18)30203-1

5. Misra A, Jayawardena R, Anoop S. Obesity in South Asia: phenotype, morbidities, and mitigation. *Curr Obes Rep*. 2019;8(1):43–52. doi:10.1007/s13679-019-0328-0

6. Kapoor N, Furler J, Paul TV, Thomas N, The OB. BMI-adiposity conundrum in South Asian populations: need for further research. *J Biosoc Sci*. 2019;51(4):619–621. doi:10.1017/S000213019000166

7. Kapoor N, Furler J, Paul TV, Thomas N, Oldenburg B. Normal weight obesity: an underrecognized problem in individuals of South Asian descent. *Clin Ther*. 2019;41(8):1638–1642. doi:10.1016/j.clinthera.2019.05.016

8. Kalra S, Unnikrishnan AG. Obesity in India: the weight of the nation. *J Med Nutraceuticals*. 2012;1(1):37. doi:10.4103/2278-019X.94634

9. Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. *Int J Epidemiol*. 2007;36(1):220–225. doi:10.1093/ije/dyl245

10. Kapoor N, Chapla A, Furler J, et al. Genetics of obesity in consanguineous populations - A road map to provide novel insights in the molecular basis and management of obesity. *EBioMedicine*. 2019;40:33–34. doi:10.1016/j.ebiom.2019.01.004

11. Gulati S, Misra A. Abdominal obesity and type 2 diabetes in Asian Indians: dietary strategies including edible oils, cooking practices and sugar intake. *Eur J Clin Nutr*. 2017;71(7):850–857. doi:10.1038/ejcn.2017.92

12. American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes —2019. *Diabetes Care*. 2019;42(Supplement):S81–S89. doi:10.2337/ dc19-S008

13. American Diabetes Association. 5. Lifestyle management: standards of medical care in diabetes—2019. *Diabetes Care*. 2019;42 (Supplement):S46–S60. doi:10.2337/dc19-S005

14. Garvey WT, Mechanick JJ, Brett EM, et al. American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. *Endocr Pract*. 2016;22(Supplement 3):1–203. doi:10.4158/EIP161365.GL

15. Bajaj S. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. *Int J Diabetes Dev Ctries*. 2018;38(Suppl1):1–115. doi:10.1007/s13410-018-0604-7

16. Herforth A, Arimond M, Álvarez-sánchez C, Coates J, Christianson K, Muchlöff E. A global review of food-based dietary guidelines. *Adv Nutr*. 2019;10(4):590–605. doi:10.1093/ advances/nmy130

17. Yumuk V, Frühbeck G, Opper JM, Woodward E, Toplak H. An EASO position statement on multidisciplinary obesity management in adults. *Obes Facts*. 2014;7(2):96–101. doi:10.1159/000362191

18. Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol*. 2019;7(5):344–355. doi:10.1016/S2213-8587(19)30068-3

19. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. *JAMA*. 2012;308(23):2489–2496. doi:10.1001/ jama.2012.67929

20. Misra A, Sharma R, Gulati S, et al. Consensus dietary guidelines for healthy living and prevention of obesity, the metabolic syndrome, diabetes, and related disorders in Asian Indians. *Diabetes Technol Ther*. 2011;13:683–694. doi:10.1089/dia.2010.0198

21. Misra A, Chowbey P, Makkar BM, et al. Consensus statement for diabetes, metabolic syndrome, diabetes, and related disorders in Asian Indians. *Indian J Endocrinol Metab*. 2012;16(Supplement1):S81–S89. doi:10.4103/1691-3199.94634

22. Kalra S, Baruah MP, Sahay R. Person centered care in the second diabetes attitudes, wishes and needs (DAWN2) study: inspiration from India. *Indian J Endocrinol Metab*. 2014;18(1):4–6. doi:10.4103/2230-8210.126519

23. Kalra S, Megaliias MH, Jawad F. Patient-centered care in diabeteology: from eminence-based, to evidence-based, to end user-based medicine. *Indian J Endocrinol Metab*. 2012;16(6):871. doi:10.4103/2230-8210.102979
26. Kalra S, Magon N, Malik S. Patient-centered care and therapeutic patient education: vadic inspiration. J Midlife Health. 2012;3(2):59–60. doi:10.4103/0976-7800.104451

27. Romano L, Marchetti M, Gualtieri P, et al. Effects of a personalized VLCKD on body composition and resting energy expenditure in the reversal of diabetes to prevent complications. Nutrients. 2019;11(7):1526. doi:10.3390/nu11071526

28. NIN. DIETARY GUIDELINES FOR INDIANS: a Manual. National Institute of Nutrition; 2011. Available from: http://ninindia.org/DietaryGuidelinesforNINwebsite.pdf. Accessed September 3, 2019.

29. Behl S, Misra A. Management of obesity in adult Asian Indians. Indian Heart J. 2017;69(4):539–544. doi:10.1016/j.ihj.2017.04.015

30. Kapoor N, Inian S, Thomas N. Chapter 28. Obesity with diabetes. In: Kapoor N, Furler J, Paul TV, Thomas N, Oldenburg B. Ethnicity-specific cut-offs that predict co-morbidities: the way forward for optimal utility of obesity indicators. J Biosci. 2019;51(4):624–626. doi:10.1002/jb.2000010178

31. Verma M, Rajput M, Kishore K, Asian KS. BMI criteria are better than WHO criteria in predicting hypertension: a cross-sectional study from rural India. J Family Med Prim Care. 2019;8(6):2095. doi:10.4103/jfmpc.jfmpc_257_19

32. Hsu WC, Araneta MRG, Kanaya AM, Chiang JL, Fujimoto W. BMI criteria are better than WHO criteria in predicting hypertension: a cross-sectional study from rural India. J Family Med Prim Care. 2019;8(6):2095. doi:10.4103/jfmpc.jfmpc_257_19

33. Kapoor N, Lotfaliany M, Sathish T, et al. Obesity indicators that best predict type 2 diabetes in an Indian population: insights from the Kerala diabetes prevention program. Diabetes Technol Ther. 2015;17(9):667–671. doi:10.1089/dia.2015.0007

34. Misra A. Ethnic-specific criteria for classification of body mass index: a perspective for Asian Indians and American Diabetes Association position statement. Diabetes Technol Ther. 2015;17(9):667–671. doi:10.1089/dia.2015.0007

35. Durrer Schutz D, Busetto L, Dicker D, et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12(1):40–66. doi:10.1159/000496183

36. Kapoor N, Lotfaliany M, Sathish T, et al. Obesity indicators that best predict type 2 diabetes in an Indian population: insights from the Kerala diabetes prevention program. J Nutr Sci. 2020;9. doi:10.1017/jns.2020.8

37. Weir CB, Jan A. BMI classification percentile and cut off points. In: StatsPearls. StatPearls Publishing; 2020. Available from: http://www.ncbi.nlm.nih.gov/books/NBK541070/. Accessed February 16, 2020.

38. Thomas N, Kapoor N, Velavan J, Asif M. A Practical Guide to Diabetes Mellitus. 8th ed. Jaypee Brothers Medical Publishers; 2018. Available from: https://www.amazon.co.uk/Practical-Guide-Diabetes-Mellitus/dp/9352701658. Accessed April 1, 2020.

39. Kapoor N, Furler J, Paul TV, Thomas N, Oldenburg B. Ethnicity-specific cut-offs that predict co-morbidities: the way forward for optimal utility of obesity indicators. J Biosci. 2019;51(4):624–626. doi:10.1002/jb.2000010178

40. Weir CB, Jan A. BMI classification percentile and cut off points. In: StatsPearls. StatPearls Publishing; 2020. Available from: http://www.ncbi.nlm.nih.gov/books/NBK541070/. Accessed February 16, 2020.

41. Thomas N, Kapoor N, Velavan J, Asif M. A Practical Guide to Diabetes Mellitus. 8th ed. Jaypee Brothers Medical Publishers; 2018. Available from: https://www.amazon.co.uk/Practical-Guide-Diabetes-Mellitus/dp/9352701658. Accessed April 1, 2020.

42. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, et al. Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med. 2015;163(11):827–835. doi:10.7326/M14-2525

43. Berstad P, Randby A, Seim Ekeland G, Ulveland H, Omland T, Almendingen K. Body fat and fat-free mass measured by bio-electric impedance spectroscopy and dual-energy X-ray absorptiometry in obese and non-obese adults. Br J Nutr. 2012;107(8):1192–1200. doi:10.1017/S000711451100417X

44. Kalra S, Kapoor N, Kota S, Das S. Person-centred obesity care – techniques, thresholds, tools and targets. Eur Endocrinol. 2020;16(1):11. doi:10.17295/EVE.2020.16.1.11
61. American Diabetes Association. 16. Diabetes advocacy: standards of medical care in diabetes—2019. *Diabetes Care*. 2019;42(Supplement 1):S182–S183. doi:10.2337/dci19-0016

62. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. *Lancet*. 2014;383(9933):1999–2007. doi:10.1016/S0140-6736(14)60613-9

63. Tsigos C, Hainer V, Basdevant A, et al. Management of obesity in adults: European clinical practice guidelines. *Obes Facts*. 2008;1(2):106–116. doi:10.1159/000026822

64. Kalra S, Choubey N. Involving culinary science as part of the diabetes care team. *J Pak Med Assoc*. 2017;67:1795–1796.

65. Coureous AP, Christian NJ, Belle SH, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. *JAMA*. 2013;310(22):2416–2425. doi:10.1001/jama.2013.280928

66. Nga VT, Dung VNT, Chu D-T, et al. School education and child obesity: a systemic review. *Diabetes Metab Syndr*. 2019;13(4):2495–2501. doi:10.1016/j.dsx.2019.07.014

67. Malhotra A, Schofield G, Lustig RH. The science against sugar, alone, is insufficient in tackling the obesity and type 2 diabetes crises - we must also overcome opposition from vested interests. *J Australasian Coll Nutr Env Med*. 2019;58(1):4.

68. Khandelwal S, Reddy KS. Eliciting a policy response for the rising epidemic of overweight-obesity in India. *Obes Rev*. 2013;14(S2):114–125. doi:10.1111/j.1467-789X.2012.012097

69. Glanz K, Yaroeh AL. Strategies for increasing fruit and vegetable intake in grocery stores and communities: policy, pricing, and recommendations. *Prev Med*. 2004;39 (Suppl 2):S88–S93. doi:10.1016/j.ympmed.2004.03.002

70. Glanz K, Yaroeh AL. Increasing fruit and vegetable intake by changing environments, policy and pricing: restaurant-based research, strategies, and recommendations. *Prev Med*. 2004;39(Suppl 2):S75–S80. doi:10.1016/j.ypmed.2004.01.004

71. Jospe MR, Roy M, Brown RC, et al. Intermittent fasting, Paleolithic, or Mediterranean diets in the real world: exploratory secondary analyses of a weight-loss trial that included choice of diet and exercise. *Am J Clin Nutr*. 2019. doi:10.1093/ajcn/nqz330

72. Jiwanmall SA, Kattula D, Nandyal MB, et al. Psychiatric burden in the morbidly obese in multidisciplinary bariatric clinic in South India. *Indian J Psychol Med*. 2018;40(2):129–133. doi:10.4103/JPJSYM.JPJSYM_187_17

73. Kahan S, Manson JE. Obesity treatment, beyond the guidelines: *JAMA*. 2019;321(14):1349–1350. doi:10.1001/jama.2019.2352

74. Lazar V, Ditu L-M, Pircalabioru GG, et al. Gut microbiota, host diseases. *Cure Opin Endocrinol Diabetes Obes*. 2013;20(5):377–388. doi:10.1097/01.med.0000433067.01671.5f

75. Obe R, Uppaluri KR. Low carbohydrate diet. In: *StatPearls*. StatPearls Publishing; 2019. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537084/. Accessed January 13, 2020.

76. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. *Diabetes Care*. 2006;29(9):2102–2107. doi:10.2337/dci06-0560

77. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. *Cell*. 2015;163(5):1079–1094. doi:10.1016/j.cell.2015.11.001

78. Drabsch T, Holzapfel C, Scientific A. Perspective of personalised gene-based dietary recommendations for weight management. *Nutrients*. 2019;11(3):617. doi:10.3390/nu11030617

79. Sharanavaz M, Arokiasamy P. Overweight/obesity: an emerging epidemic in India. *J Clin Diug Res*. 2018;12(11). doi:10.7860/CJR/2018/37014.12201

80. Kumar A, Kalra S, Unnikrishnan AG. Metabolic state of the nation: results of the national family health survey-4. *Indian J Endocrinol Metab*. 2016;20(4):429. doi:10.4103/2230-8210.183453

81. Ardahan M, Konal E. The prevalence of hypertension and obesity and effective factors: a cross-sectional bazaar study. *J Pak Med Assoc*. 2019;69(7):1018–1021.

82. Tanwi TS, Chakrabarty S, Hasanuzzaman S, Salimmarsh S, Wina S. Socioeconomic correlates of overweight and obesity among ever-married urban women in Bangladesh. *BMC Public Health*. 2019;19(1):842. doi:10.1186/s12889-019-7221-3

83. Saeed KMI. Pattern of adult obesity in Kabul capital of Afghanistan: a cross sectional study using who stepwise tool. *JOSR J Pharm*. 2016;6(11):89–96.

84. Saeed KMI, Rasooly MH, Nejaby MJ. Profile of risk factors for noncommunicable diseases in major cities of Afghanistan: WHO STEPwise approach. *East Mediterr Health J*. 2020;26(4):388–399. doi:10.26719/emhj.20.005

85. Rawal LB, Kanda K, Mahumud RA, et al. Prevalence of underweight, overweight and obesity and their associated risk factors in Nepalese adults: data from a Nationwide Survey, 2016. *PLoS One*. 2018;13(11):e0205912. doi:10.1371/journal.pone.0205912

86. World Health Organization. World Health Organization – diabetes country profiles-Bhutan. 2016. Available from: https://www.who.int/diabetes/country-profiles/btn_en.pdf. Accessed April 1, 2020.

87. Sithey G, Li M, Thow AM. Strengthening non-communicable disease policy with lessons from Bhutan: linking gross national happiness and health policy action. *J Public Health Policy*. 2018;39(3):327–342. doi:10.1177/0144875517752022

88. Sithey G, Thow AM, Sharma J, Lhazin K, Li M. Taking action on prevention and control of noncommunicable diseases in Bhutan by strengthening gross national happiness. *Bhutan Health J*. 2018;4(2):46–50. doi:10.47811/bhj.69

89. Canning KL, Brown RE, Wharton S, Sharma AM, Kuk JL. Edmonton obesity staging system prevalence and association with weight loss in a publicly funded referral-based obesity clinic. *J Obes*. 2015;2015:1–7. doi:10.1155/2015/619734

90. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. *Int J Obes*. 2009;33(3):289–295. doi:10.1038/ijs.2009.2

91. Daniel S, Soleymani T, Garvey WT. The role of gut microbiota in the development of obesity and type 2 diabetes. *J Obes*. 2016;2018(4):1–12. doi:10.1155/2019/2046428

92. Saithey G, Thow AM, Sharma J, Lhazin K, Li M. Taking action on prevention and control of noncommunicable diseases in Bhutan by strengthening gross national happiness. *Bhutan Health J*. 2018;4(2):46–50. doi:10.47811/bhj.69

93. Sithey G, Thow AM, Sharma J, Lhazin K, Li M. Taking action on prevention and control of noncommunicable diseases in Bhutan by strengthening gross national happiness. *Bhutan Health J*. 2018;4(2):46–50. doi:10.47811/bhj.69

94. Sithey G, Thow AM, Sharma J, Lhazin K, Li M. Taking action on prevention and control of noncommunicable diseases in Bhutan by strengthening gross national happiness. *Bhutan Health J*. 2018;4(2):46–50. doi:10.47811/bhj.69
99. Davis JN, Alexander KE, Ventura EE, Toledo-Corraal CM, Goran MI. Inverse relation between dietary fiber intake and visceral adiposity in overweight Latino youth. *Am J Clin Nutr*. 2009;90(5):1160–1166. doi:10.3945/ajcn.2009.28133

100. Goldstein T, Kark JD, Berry EM, Adler B, Ziv E, Raz I. The effect of a low carbohydrate energy-unrestricted diet on weight loss in obese type 2 diabetes patients – a randomized controlled trial. *Eur J Clin Nutr Metab*. 2011;65(4):e178–e186. doi:10.1016/j.eclinm.2011.04.003

101. Meng Y, Bai H, Wang S, Li Z, Wang Q, Chen L. Efficacy of low carbohydrate diet for type 2 diabetes mellitus management: a systematic review and meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract*. 2017;131:124–131. doi:10.1016/j.diabres.2017.07.006

102. Bueno NB, De melo ISV, da Rocha Ataide T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. *Br J Nutr*. 2013;110(7):1178–1187. doi:10.1017/S0007114513000548

103. Yabe D, Iwasaki M, Kuwata H, et al. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: a randomized, open-label, 3-arm parallel comparative, exploratory study. *Diabetes Obes Metab*. 2017;19(9):739–743. doi:10.1111/dom.12848

104. Davis NJ, Tomuta N, Schechter C, et al. Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes. *Diabetes Care*. 2009;32(7):1147–1152. doi:10.2337/dc08-2108

105. Murphy EA, Jenkins TJ. A ketogenic diet for reducing obesity and maintaining capacity for physical activity: hype or hope? *Curr Opin Clin Nutr Metab Care*. 2019;22(4):314–319. doi:10.1097/MCO.0000000000000572

106. Gupta L, Khandelwal D, Lal PR, Kalra S, Dutta D. Palaeolithic diet: epidemiological and molecular aspects. *Mol Aspects Med*. 2019;67:1–55. doi:10.1016/j.mam.2019.06.001

107. Obert J, Pearlman M, Obert L, Chapin S. Popular weight loss strategies: a review of four weight loss techniques. *Curr Gastroenterol Rep*. 2017;19(12):61. doi:10.1007/s11894-017-0603-8

108. Kuchkuntla AR, Berry EM, Adler B, Ziv E, Raz I. The effect of a low carbohydrate energy-unrestricted diet on weight loss in obese type 2 diabetes patients – a randomized controlled trial. *Eur J Clin Nutr Metab*. 2011;65(4):e178–e186. doi:10.1016/j.eclinm.2011.04.003

109. Serra-Majem L, Román-Vílchez I, Staweyczyk-Kazmierczak I, Staweyczyk-Kazmierczak K, Banasik E, Dobrowolska A. Dietary support in elderly patients with inflammatory bowel disease. *Nutrients*. 2019;11(6):1421. doi:10.3390/nu11061421

110. Campbell AP. DASH eating plan: an eating pattern for diabetes management. *Diabetes Spectr*. 2017;30(2):76–81. doi:10.2337/ds16-0084

111. Perry C, Guider GV. Positive improvements on body composition and muscle strength in older adults consuming the dietary approaches to stop hypertension diet containing beef (OR18-01-19). *Curr Dev Nutr*. 2019;5(Supplement_1):nzz028–OR18. doi:10.1093/cdn/nzz028.0R18-01-19

112. Caprio M, Infante M, Moriconi E, et al. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). *J Endocrinol Invest*. 2019;42(11):1365–1386. doi:10.1007/s40618-019-01061-2

113. Muscogiuri G, Barrea L, Laudsido D, et al. The management of very low-carbohydrate ketogenic diet in obesity outpatient clinic: a practical guide. *J Transl Med*. 2019;17(1):356. doi:10.1186/s12967-019-2104-z

114. Luat AF, Choudhari PK, Mahajan RR, et al. Effect of a very-low-calorie diet on restoration of normoglycemia in obese subjects with type 2 diabetes. *Indian J Endocrinol Metab*. 2017;21(5):776. doi:10.4103/ijem.IJEM_206_17

115. Agrawal S, Millett CJ, Dhillon PK, Subramanian S, Ebrahim S. Type of vegetarian diet, obesity and diabetes in adult Indian population. *Nutr J*. 2014;13(1):89. doi:10.1186/1475-2891-13-89

116. Turner-McGrievy G, Mandes T, Cimarcho A. A plant-based diet for overweight and obesity prevention and treatment. *J Geriatr Cardiol*. 2017;14(5):369–374. doi:10.11909/j.issn.1671-5411.2017.05.002